[en] Mutations in PRKN cause the second most common genetic form of Parkinson's disease (PD)—a debilitating movement disorder that is on the rise due to population aging in the industrial world. PRKN codes for an E3 ubiquitin ligase that has been well established as a key regulator of mitophagy. Together with PTEN-induced kinase 1 (PINK1), Parkin controls the lysosomal degradation of depolarized mitochondria. But Parkin's functions go well beyond mitochondrial clearance: the versatile protein is involved in mitochondria-derived vesicle formation, cellular metabolism, calcium homeostasis, mitochondrial DNA maintenance, mitochondrial biogenesis, and apoptosis induction. Moreover, Parkin can act as a modulator of different inflammatory pathways. In the current review, we summarize the latest literature concerning the diverse roles of Parkin in maintaining a healthy mitochondrial pool. Moreover, we discuss how these recent discoveries may translate into personalized therapeutic approaches not only for PRKN-PD patients but also for a subset of idiopathic cases.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Pereira, Sandro L.; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Molecular and Functional Neurobiology Group
Grossmann, Dajana
Delcambre, Sylvie ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Molecular and Functional Neurobiology
Hermann, Andreas
Grünewald, Anne ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Molecular and Functional Neurobiology
External co-authors :
yes
Language :
English
Title :
Novel insights into Parkin-mediated mitochondrial dysfunction and neuroinflammation in Parkinson's disease
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., Shimizu, N., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998), 605–608.
Kasten, M., Hartmann, C., Hampf, J., Schaake, S., Westenberger, A., Vollstedt, E.J., Balck, A., Domingo, A., Vulinovic, F., Dulovic, M., et al. Genotype-phenotype relations for the Parkinson's disease genes parkin, PINK1, DJ1: MDSGene systematic review. Mov Disord 33 (2018), 730–741.
Wasner, K., Grunewald, A., Klein, C., Parkin-linked Parkinson's disease: from clinical insights to pathogenic mechanisms and novel therapeutic approaches. Neurosci Res 159 (2020), 34–39.
Grunewald, A., Kasten, M., Ziegler, A., Klein, C., Next-generation phenotyping using the parkin example: time to catch up with genetics. JAMA Neurol 70 (2013), 1186–1191.
Riley, B.E., Lougheed, J.C., Callaway, K., Velasquez, M., Brecht, E., Nguyen, L., Shaler, T., Walker, D., Yang, Y., Regnstrom, K., et al. Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat Commun, 4, 2013, 1982.
Darios, F., Corti, O., Lucking, C.B., Hampe, C., Muriel, M.P., Abbas, N., Gu, W.J., Hirsch, E.C., Rooney, T., Ruberg, M., et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12 (2003), 517–526.
Narendra, D., Tanaka, A., Suen, D.F., Youle, R.J., Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183 (2008), 795–803.
Ham, S.J., Lee, D., Yoo, H., Jun, K., Shin, H., Chung, J., Decision between mitophagy and apoptosis by Parkin via VDAC1 ubiquitination. Proc Natl Acad Sci U S A 117 (2020), 4281–4291.
Rakovic, A., Shurkewitsch, K., Seibler, P., Grunewald, A., Zanon, A., Hagenah, J., Krainc, D., Klein, C., Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. J Biol Chem 288 (2013), 2223–2237.
Sulkshane, P., Ram, J., Thakur, A., Reis, N., Kleifeld, O., Glickman, M.H., Ubiquitination and receptor-mediated mitophagy converge to eliminate oxidation-damaged mitochondria during hypoxia. Redox Biol, 45, 2021, 102047.
Onishi, M., Yamano, K., Sato, M., Matsuda, N., Okamoto, K., Molecular mechanisms and physiological functions of mitophagy. EMBO J, 40, 2021, e104705.
Zachari, M., Ktistakis, N.T., Mammalian mitophagosome formation: a focus on the early signals and steps. Front Cell Dev Biol, 8, 2020, 171.
Laker, R.C., Drake, J.C., Wilson, R.J., Lira, V.A., Lewellen, B.M., Ryall, K.A., Fisher, C.C., Zhang, M., Saucerman, J.J., Goodyear, L.J., et al. Ampk phosphorylation of Ulk1 is required for targeting of mitochondria to lysosomes in exercise-induced mitophagy. Nat Commun, 8, 2017, 548.
Iorio, R., Celenza, G., Petricca, S., Mitophagy: molecular mechanisms, new concepts on parkin activation and the emerging role of AMPK/ULK1 Axis. Cells, 2021, 11.
Imberechts, D., Kinnart, I., Wauters, F., Terbeek, J., Manders, L., Wierda, K., Eggermont, K., Madeiro, R.F., Sue, C., Verfaillie, C., et al. DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy. Brain 145 (2022), 4368–4384.
van der Merwe, C., Jalali Sefid Dashti, Z., Christoffels, A., Loos, B., Bardien, S., Evidence for a common biological pathway linking three Parkinson's disease-causing genes: parkin, PINK1 and DJ-1. Eur J Neurosci 41 (2015), 1113–1125.
Thomas, K.J., McCoy, M.K., Blackinton, J., Beilina, A., van der Brug, M., Sandebring, A., Miller, D., Maric, D., Cedazo-Minguez, A., Cookson, M.R., DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet 20 (2011), 40–50.
Matheoud, D., Sugiura, A., Bellemare-Pelletier, A., Laplante, A., Rondeau, C., Chemali, M., Fazel, A., Bergeron, J.J., Trudeau, L.E., Burelle, Y., et al. Parkinson's disease-related proteins PINK1 and parkin repress mitochondrial antigen presentation. Cell 166 (2016), 314–327.
Scarpulla, R.C., Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 88 (2008), 611–638.
Kuroda, Y., Mitsui, T., Kunishige, M., Shono, M., Akaike, M., Azuma, H., Matsumoto, T., Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 15 (2006), 883–895.
Rothfuss, O., Fischer, H., Hasegawa, T., Maisel, M., Leitner, P., Miesel, F., Sharma, M., Bornemann, A., Berg, D., Gasser, T., et al. Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 18 (2009), 3832–3850.
Shin, J.H., Ko, H.S., Kang, H., Lee, Y., Lee, Y.I., Pletinkova, O., Troconso, J.C., Dawson, V.L., Dawson, T.M., PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144 (2011), 689–702.
Pirooznia, S.K., Yuan, C., Khan, M.R., Karuppagounder, S.S., Wang, L., Xiong, Y., Kang, S.U., Lee, Y., Dawson, V.L., Dawson, T.M., PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. Mol Neurodegener, 15, 2020, 17.
Kumar, M., Acevedo-Cintron, J., Jhaldiyal, A., Wang, H., Andrabi, S.A., Eacker, S., Karuppagounder, S.S., Brahmachari, S., Chen, R., Kim, H., et al. Defects in mitochondrial biogenesis drive mitochondrial alterations in PARKIN-deficient human dopamine neurons. Stem Cell Rep 15 (2020), 629–645.
Wasner, K., Smajic, S., Ghelfi, J., Delcambre, S., Prada-Medina, C.A., Knappe, E., Arena, G., Mulica, P., Agyeah, G., Rakovic, A., et al. Parkin deficiency impairs mitochondrial DNA dynamics and propagates inflammation. Mov Disord 37 (2022), 1405–1415.
Wan, W., Hua, F., Fang, P., Li, C., Deng, F., Chen, S., Ying, J., Wang, X., Regulation of mitophagy by sirtuin family proteins: a vital role in aging and age-related diseases. Front Aging Neurosci, 14, 2022, 845330.
Suen, D.F., Narendra, D.P., Tanaka, A., Manfredi, G., Youle, R.J., Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. Proc Natl Acad Sci U S A 107 (2010), 11835–11840.
Trinh, J., Hicks, A.A., Konig, I.R., Delcambre, S., Luth, T., Schaake, S., Wasner, K., Ghelfi, J., Borsche, M., Vilarino-Guell, C., et al. Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1/PRKN-linked Parkinson's disease. Brain, 2022.
Scott, L., Karuppagounder, S.S., Neifert, S., Kang, B.G., Wang, H., Dawson, V.L., Dawson, T.M., The absence of parkin does not promote dopamine or mitochondrial dysfunction in PolgA(D257A/D257A) mitochondrial mutator mice. J Neurosci 42 (2022), 9263–9277.
Meles, S.K., Renken, R.J., Pagani, M., Teune, L.K., Arnaldi, D., Morbelli, S., Nobili, F., van Laar, T., Obeso, J.A., Rodriguez-Oroz, M.C., et al. Abnormal pattern of brain glucose metabolism in Parkinson's disease: replication in three European cohorts. Eur J Nucl Med Mol Imag 47 (2020), 437–450.
Borghammer, P., Chakravarty, M., Jonsdottir, K.Y., Sato, N., Matsuda, H., Ito, K., Arahata, Y., Kato, T., Gjedde, A., Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct 214 (2010), 303–317.
Hang, L., Thundyil, J., Goh, G.W.Y., Lim, K.L., AMP kinase activation is selectively disrupted in the ventral midbrain of mice deficient in parkin or PINK1 expression. NeuroMolecular Med 21 (2019), 25–32.
Smith, A.M., Depp, C., Ryan, B.J., Johnston, G.I., Alegre-Abarrategui, J., Evetts, S., Rolinski, M., Baig, F., Ruffmann, C., Simon, A.K., et al. Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells. Mov Disord 33 (2018), 1580–1590.
Borsche, M., Martens, A., Hormann, P., Bruckmann, T., Lohmann, K., Tunc, S., Klein, C., Hiller, K., Balck, A., In vivo investigation of glucose metabolism in idiopathic and PRKN-related Parkinson's disease. Mov Disord, 2023.
Zhang, C., Lin, M., Wu, R., Wang, X., Yang, B., Levine, A.J., Hu, W., Feng, Z., Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci U S A 108 (2011), 16259–16264.
Liu, K., Li, F., Han, H., Chen, Y., Mao, Z., Luo, J., Zhao, Y., Zheng, B., Gu, W., Zhao, W., Parkin regulates the activity of pyruvate kinase M2. J Biol Chem 291 (2016), 10307–10317.
Bogetofte, H., Jensen, P., Ryding, M., Schmidt, S.I., Okarmus, J., Ritter, L., Worm, C.S., Hohnholt, M.C., Azevedo, C., Roybon, L., et al. PARK2 mutation causes metabolic disturbances and impaired survival of human iPSC-derived neurons. Front Cell Neurosci, 13, 2019, 297.
Okarmus, J., Havelund, J.F., Ryding, M., Schmidt, S.I., Bogetofte, H., Heon-Roberts, R., Wade-Martins, R., Cowley, S.A., Ryan, B.J., Faergeman, N.J., et al. Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: altered mitochondrial and energy metabolism. Stem Cell Rep 16 (2021), 1510–1526.
Narendra, D.P., Thayer, J.A., Midbrain on fire: mtDNA ignites neuroinflammation in PRKN-P. Mov Disord 37 (2022), 1332–1334.
Zanon, A., Kalvakuri, S., Rakovic, A., Foco, L., Guida, M., Schwienbacher, C., Serafin, A., Rudolph, F., Trilck, M., Grunewald, A., et al. SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila. Hum Mol Genet 26 (2017), 2412–2425.
Wu, J., Jin, Z., Zheng, H., Yan, L.J., Sources and implications of NADH/NAD(+) redox imbalance in diabetes and its complications. Diabetes Metab Syndr Obes 9 (2016), 145–153.
Kim, K.Y., Stevens, M.V., Akter, M.H., Rusk, S.E., Huang, R.J., Cohen, A., Noguchi, A., Springer, D., Bocharov, A.V., Eggerman, T.L., et al. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J Clin Invest 121 (2011), 3701–3712.
Okuzumi, A., Hatano, T., Ueno, S.I., Ogawa, T., Saiki, S., Mori, A., Koinuma, T., Oji, Y., Ishikawa, K.I., Fujimaki, M., et al. Metabolomics-based identification of metabolic alterations in PARK2. Ann Clin Transl Neurol 6 (2019), 525–536.
Basso, V., Marchesan, E., Peggion, C., Chakraborty, J., von Stockum, S., Giacomello, M., Ottolini, D., Debattisti, V., Caicci, F., Tasca, E., et al. Regulation of ER-mitochondria contacts by parkin via Mfn2. Pharmacol Res 138 (2018), 43–56.
Signorile, A., Ferretta, A., Pacelli, C., Capitanio, N., Tanzarella, P., Matrella, M.L., Valletti, A., De Rasmo, D., Cocco, T., Resveratrol treatment in human parkin-mutant fibroblasts modulates cAMP and calcium homeostasis regulating the expression of mitochondria-associated membranes resident proteins. Biomolecules, 2021, 11.
Cali, T., Ottolini, D., Negro, A., Brini, M., Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics. Biochim Biophys Acta 1832 (2013), 495–508.
Celardo, I., Costa, A.C., Lehmann, S., Jones, C., Wood, N., Mencacci, N.E., Mallucci, G.R., Loh, S.H., Martins, L.M., Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease. Cell Death Dis, 7, 2016, e2271.
Gautier, C.A., Erpapazoglou, Z., Mouton-Liger, F., Muriel, M.P., Cormier, F., Bigou, S., Duffaure, S., Girard, M., Foret, B., Iannielli, A., et al. The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations. Hum Mol Genet 25 (2016), 2972–2984.
McLelland, G.L., Goiran, T., Yi, W., Dorval, G., Chen, C.X., Lauinger, N.D., Krahn, A.I., Valimehr, S., Rakovic, A., Rouiller, I., et al. Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy. Elife, 7, 2018.
Sandebring, A., Dehvari, N., Perez-Manso, M., Thomas, K.J., Karpilovski, E., Cookson, M.R., Cowburn, R.F., Cedazo-Minguez, A., Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. FEBS J 276 (2009), 5041–5052.
Rybarski, M., Mrohs, D., Osenberg, K., Hemmersbach, M., Pfeffel, K., Steinkamp, J., Schmidt, D., Violou, K., Schaning, R., Schmidtke, K., et al. Loss of parkin causes endoplasmic reticulum calcium dyshomeostasis by upregulation of reticulocalbin 1. Eur J Neurosci, 2023.
Matteucci, A., Patron, M., Vecellio Reane, D., Gastaldello, S., Amoroso, S., Rizzuto, R., Brini, M., Raffaello, A., Cali, T., Parkin-dependent regulation of the MCU complex component MICU1. Sci Rep, 8, 2018, 14199.
Wang, X., Winter, D., Ashrafi, G., Schlehe, J., Wong, Y.L., Selkoe, D., Rice, S., Steen, J., LaVoie, M.J., Schwarz, T.L., PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147 (2011), 893–906.
Kornmann, B., Osman, C., Walter, P., The conserved GTPase Gem1 regulates endoplasmic reticulum-mitochondria connections. Proc Natl Acad Sci U S A 108 (2011), 14151–14156.
Lee, S., Lee, K.S., Huh, S., Liu, S., Lee, D.Y., Hong, S.H., Yu, K., Lu, B., Polo kinase phosphorylates Miro to control ER-mitochondria contact sites and mitochondrial Ca(2+) homeostasis in neural stem cell development. Dev Cell 37 (2016), 174–189.
Niescier, R.F., Hong, K., Park, D., Min, K.T., MCU interacts with Miro1 to modulate mitochondrial functions in neurons. J Neurosci 38 (2018), 4666–4677.
Paillard, M., Csordas, G., Huang, K.T., Varnai, P., Joseph, S.K., Hajnoczky, G., MICU1 interacts with the D-ring of the MCU pore to control its Ca(2+) flux and sensitivity to Ru360. Mol Cell 72 (2018), 778–785 e773.
Kim, J., Gupta, R., Blanco, L.P., Yang, S., Shteinfer-Kuzmine, A., Wang, K., Zhu, J., Yoon, H.E., Wang, X., Kerkhofs, M., et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science 366 (2019), 1531–1536.
McArthur, K., Whitehead, L.W., Heddleston, J.M., Li, L., Padman, B.S., Oorschot, V., Geoghegan, N.D., Chappaz, S., Davidson, S., San Chin, H., et al. BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Science, 359, 2018.
Johnson, B.N., Berger, A.K., Cortese, G.P., Lavoie, M.J., The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Proc Natl Acad Sci U S A 109 (2012), 6283–6288.
Bernardini, J.P., Brouwer, J.M., Tan, I.K., Sandow, J.J., Huang, S., Stafford, C.A., Bankovacki, A., Riffkin, C.D., Wardak, A.Z., Czabotar, P.E., et al. Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy. EMBO J, 38, 2019.
West, A.P., Khoury-Hanold, W., Staron, M., Tal, M.C., Pineda, C.M., Lang, S.M., Bestwick, M., Duguay, B.A., Raimundo, N., MacDuff, D.A., et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 520 (2015), 553–557.
Szego, E.M., Malz, L., Bernhardt, N., Rosen-Wolff, A., Falkenburger, B.H., Luksch, H., Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice. Elife, 2022, 11.
Borsche, M., Konig, I.R., Delcambre, S., Petrucci, S., Balck, A., Bruggemann, N., Zimprich, A., Wasner, K., Pereira, S.L., Avenali, M., et al. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. Brain 143 (2020), 3041–3051.
Picard, M., Blood mitochondrial DNA copy number: what are we counting?. Mitochondrion 60 (2021), 1–11.
Trumpff, C., Michelson, J., Lagranha, C.J., Taleon, V., Karan, K.R., Sturm, G., Lindqvist, D., Fernstrom, J., Moser, D., Kaufman, B.A., et al. Stress and circulating cell-free mitochondrial DNA: a systematic review of human studies, physiological considerations, and technical recommendations. Mitochondrion 59 (2021), 225–245.
Michelson, J., Rausser, S., Peng, A., Yu, T., Sturm, G., Trumpff, C., Kaufman, B.A., Rai, A.J., Picard, M., MitoQuicLy: a high-throughput method for quantifying cell-free DNA from human plasma, serum, and saliva. 2023, bioRxiv.
West, A.P., Shadel, G.S., Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat Rev Immunol 17 (2017), 363–375.
Panicker, N., Kam, T.I., Wang, H., Neifert, S., Chou, S.C., Kumar, M., Brahmachari, S., Jhaldiyal, A., Hinkle, J.T., Akkentli, F., et al. Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease. Neuron 110 (2022), 2422–2437 e2429.
von Herrmann, K.M., Salas, L.A., Martinez, E.M., Young, A.L., Howard, J.M., Feldman, M.S., Christensen, B.C., Wilkins, O.M., Lee, S.L., Hickey, W.F., et al. NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease. NPJ Parkinsons Dis, 4, 2018, 24.
Shimada, K., Crother, T.R., Karlin, J., Dagvadorj, J., Chiba, N., Chen, S., Ramanujan, V.K., Wolf, A.J., Vergnes, L., Ojcius, D.M., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36 (2012), 401–414.
Picard, M., Shirihai, O.S., Mitochondrial signal transduction. Cell Metabol 34 (2022), 1620–1653.
Wang, Q., Lu, M., Zhu, X., Gu, X., Zhang, T., Xia, C., Yang, L., Xu, Y., Zhou, M., The role of microglia immunometabolism in neurodegeneration: focus on molecular determinants and metabolic intermediates of metabolic reprogramming. Biomed Pharmacother, 153, 2022, 113412.
Brakedal, B., Dolle, C., Riemer, F., Ma, Y., Nido, G.S., Skeie, G.O., Craven, A.R., Schwarzlmuller, T., Brekke, N., Diab, J., et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metabol 34 (2022), 396–407 e396.
Chen, H., Zhang, S.M., Hernan, M.A., Schwarzschild, M.A., Willett, W.C., Colditz, G.A., Speizer, F.E., Ascherio, A., Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 (2003), 1059–1064.
Magana, J.C., Deus, C.M., Gine-Garriga, M., Montane, J., Pereira, S.P., Exercise-boosted mitochondrial remodeling in Parkinson's disease. Biomedicines, 2022, 10.
Dawson, T.M., Dawson, V.L., Parkin plays a role in sporadic Parkinson's disease. Neurodegener Dis 13 (2014), 69–71.